GTHX / G1 Therapeutics: Biotech With FDA Approved Drug Plus Additional Potential

G1 Therapeutics, Inc. (NASDAQ:GTHX ) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET Company Participants Will Roberts – Vice President more_horizontal

Ready to dive into the volatile world of penny stocks? You've got your work cut out for yourself if this is your first foray into the stock market. more_horizontal

G1 Therapeutics (GTHX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of a loss of $0.17 per share. This co more_horizontal

RESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today annou more_horizontal

GTHX halted the CRC trial on low survival benefits. There are reasons its other trials with trilaciclib could be more positive. more_horizontal

G1 Therapeutics (GTHX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss more_horizontal

G1 Therapeutics (GTHX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might driv more_horizontal

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 14.12% and 6.64%, respectively, for the quarter ended December 2022. Do the numbers more_horizontal